Cytisinicline Has 13 Days. So Does the Generation That Started Vaping in Eighth Grade.

On June 20, 2026 — thirteen days from today — the FDA will either approve or decline cytisinicline, a plant-derived compound for nicotine dependence that would become the first new smoking cessation pharmacotherapy in approximately two decades. The last time this happened, George W. Bush was president, the iPhone hadn’t been invented, and nicotine delivery was still primarily a cigarette problem.

The world has changed in ways that make the timing of this decision almost ironic.

What cytisinicline is and how it works

Cytisinicline is extracted from the seeds of Laburnum anagyroides, the golden chain tree, a plant that European folk medicine has used for nicotine withdrawal for more than a century. The compound is a partial agonist of the α4β2 nicotinic acetylcholine receptor — the same receptor targeted by varenicline (Chantix), the last FDA-approved cessation medication approved in 2006. The mechanism: cytisinicline binds to the receptor with high affinity, triggering a partial dopamine release that blunts withdrawal symptoms and reduces the reward from smoking, without the full activation that nicotine itself produces.

The analogy to buprenorphine in opioid treatment is imperfect but structurally similar: a partial agonist that satisfies enough of the neurological need to make quitting tolerable, while reducing the reinforcing properties of the addictive substance. The concept works. The question, for twenty years, was whether anyone would develop it properly for a Western regulatory approval.

Achieve Life Sciences ran two Phase 3 trials — ORCA-2 and ORCA-3 — that showed cytisinicline produced significantly improved abstinence rates versus placebo across 12-week and 24-week treatment courses. The FDA accepted the NDA in September 2025, granted Breakthrough Therapy designation, and set the Prescription Drug User Fee Act target date of June 20. The company also received an FDA Commissioner’s National Priority Voucher for e-cigarette and vaping cessation — a recent designation for treatments addressing public health priorities — which suggests the FDA views the vaping indication as at least as significant as the smoking one.

The psychology of nicotine addiction, which is not what most people think it is

Nicotine is often described as one of the most addictive substances known, and then the observation is typically left there, as a data point. It’s worth spending a moment on why — because the mechanism of nicotine addiction is the mechanism of why it’s so hard to treat, and understanding it changes how you think about what a new pharmacotherapy actually offers.

When nicotine reaches the brain — which takes approximately seven to ten seconds after inhalation, faster than any intravenous drug — it binds to nicotinic acetylcholine receptors and triggers a dopamine cascade in the nucleus accumbens. The brain is, in a very literal sense, rewarded. But the crucial feature of nicotine is its half-life: the drug clears the system within about two hours. Where other drugs maintain elevated receptor activation for hours or days, nicotine forces repeated dosing just to maintain baseline neurotransmitter equilibrium. A pack-a-day smoker delivers nicotine to their brain approximately 200 times daily.

The consequence is neuroadaptation that is both rapid and profound. The brain upregulates nicotinic receptors in response to chronic exposure — growing more of them to compensate for the artificial stimulation. When nicotine is removed, the excess receptors activate a withdrawal syndrome: irritability, anxiety, depressed mood, difficulty concentrating, sleep disruption. These aren’t psychological symptoms in the sense of being “in your head.” They’re biological outputs from a brain that has reorganized itself around a substance and is now operating without it.

The Yale Medicine researchers who study adolescent vaping describe the resulting addiction cycle in terms that young users often don’t understand: the anxiety that vaping seems to relieve was, in many cases, caused by the vaping. Nicotine withdrawal produces anxiety. Nicotine delivery relieves it. The subjective experience — vaping makes me feel calmer — is technically accurate and profoundly misleading about what’s actually happening.

The subjective experience — vaping makes me feel calmer — is technically accurate and profoundly misleading about what’s actually happening.

Dr. Suchitra Krishnan-Sarin, who directs Yale’s Tobacco Research Program, has described the challenge of adolescent nicotine cessation in precisely this framework: “The young people we see aren’t just addicted to nicotine. They’ve organized their emotional regulation around it. When they try to quit, the withdrawal looks like anxiety disorder. In some cases it is anxiety disorder, triggered by nicotine dependence. Distinguishing the two requires clinical attention that most schools and pediatric practices aren’t equipped to provide.”

The population that didn’t exist when varenicline was approved

In 2006, smoking cessation pharmacotherapy was a cigarette problem. The at-risk population was older, the delivery mechanism was slow, and the addiction timeline was typically measured in years before significant health consequences became visible.

Twenty years later, the patient population that a new cessation medication would treat looks completely different. The CDC estimated that 3.65 million middle and high school students used e-cigarettes in 2024. The Truth Initiative has documented that vaping products deliver nicotine more efficiently than traditional cigarettes — modern pod-based devices deliver nicotine at concentrations up to three times higher than combustible cigarettes, using nicotine salts that are absorbed more rapidly and produce less throat irritation, making it easier to inhale deeply and frequently. A generation that started vaping at 13 or 14 has, by 18, a nicotine exposure history and a neuroadaptive pattern that matches or exceeds what a smoker would have at 30.

The emergence of this population is exactly what the FDA Commissioner’s National Priority Voucher for cytisinicline’s vaping cessation indication signals: the regulatory agency sees the vaping epidemic as an urgent public health problem requiring dedicated pharmacological tools, not just behavioral interventions and smoking prevention messaging.

Why the pharmacotherapy gap lasted 20 years

Varenicline was approved in 2006 and immediately dominated the cessation pharmacotherapy market. It also generated significant controversy: post-market surveillance found associations with neuropsychiatric adverse events — mood changes, depression, suicidal ideation — that led to a black box warning in 2009. The black box (later removed in 2016 after a large-scale EAGLES trial found the risk was lower than initial reports suggested) chilled prescribing and chilled commercial investment in the category. If the leading drug in the space had neuropsychiatric safety signals, developing a competitor required proving superiority on both efficacy and safety against a complicated backdrop.

Cytisinicline’s safety profile appears cleaner, at least in the Phase 3 data: the ORCA trials didn’t show the mood and behavior adverse events that had complicated varenicline. The compound is also shorter-acting and cheaper to synthesize than varenicline, which has implications for access in populations that can’t afford branded smoking cessation medications.

What approval would actually change — and what it wouldn’t

FDA approval of cytisinicline on June 20 would add a pharmacological option that the nicotine and tobacco treatment field has lacked for two decades. It would give clinicians a second evidence-based medication option beyond varenicline, and a first-line pharmacotherapy option for the vaping cessation indication, where the evidence base has been almost entirely behavioral.

What it wouldn’t immediately change is access. Pharmacotherapy for tobacco and nicotine dependence has historically been underreimbursed in Medicaid and underutilized in primary care. Getting approved is a different problem from getting prescribed, and getting prescribed is a different problem from getting to the young adult who’s been vaping since middle school and doesn’t currently have a primary care physician.

The 20-year gap in cessation pharmacotherapy was not primarily a scientific failure. The science of nicotinic receptor pharmacology has been well-developed for decades; cytisinicline’s mechanism was understood before varenicline was even approved. The gap was a market failure: no one had sufficient financial incentive to run the development process for a drug with a well-established generic competitor in its category, in a regulatory environment complicated by the varenicline safety controversy, for a patient population that wasn’t seen as commercially attractive.

The science of nicotinic receptor pharmacology has been well-developed for decades; cytisinicline’s mechanism was understood before varenicline was even approved.

The vaping epidemic changed the math. Three million adolescents and young adults who will spend the next decade trying to quit something that rewired their dopamine systems in high school represent both a public health emergency and, for a pharmaceutical company willing to run the trials, a significant commercial opportunity.

On June 20, the FDA will tell us whether cytisinicline cleared the bar. The question that comes after approval — who pays for it, who prescribes it, and whether it reaches the 8th-grader who started vaping in 2022 — is the harder one. That question doesn’t have a PDUFA date.